Next Article in Journal
Bovine Viral Diarrhea/Mucosal Disease—A Commentary of the Guest Editor
Next Article in Special Issue
Evaluation of Meningococcal Serogroup C Bactericidal Antibodies after Primary Vaccination: A Multicentre Study, Italy
Previous Article in Journal
Shoulder Injury Related to COVID-19 Vaccine Administration: A Case Series
Previous Article in Special Issue
Flu and Pneumococcal Vaccine Coverage in Scleroderma Patients Still Need to Be Prompted: A Systematic Review

Global Pandemic Preparedness: Optimizing Our Capabilities and the Influenza Experience

Seqirus Ltd., Parkville, VIC 3052, Australia
Department of Immunology and Microbiology, University of Melbourne, Parkville, VIC 3052, Australia
Seqirus Ltd., Maidenhead SL6 8AA, UK
The Francis Crick Institute, London NW1 1AT, UK
WHO Collaborating Centre for Reference and Research on Influenza, Melbourne, VIC 3000, Australia
Author to whom correspondence should be addressed.
Academic Editors: Gouri Rani Banik and Harunor Rashid
Vaccines 2022, 10(4), 589;
Received: 3 March 2022 / Revised: 5 April 2022 / Accepted: 6 April 2022 / Published: 12 April 2022
(This article belongs to the Special Issue Infectious Diseases: The Role of Vaccines and Complementary Measures)
The coronavirus disease 2019 (COVID-19) pandemic has prompted rapid investigation and deployment of vaccine platforms never before used to combat human disease. The severe impact on the health system and the high economic cost of non-pharmaceutical interventions, such as lockdowns and international border closures employed to mitigate the spread of COVID-19 prior to the arrival of effective vaccines, have led to calls for development and deployment of novel vaccine technologies as part of a “100-day response ambition” for the next pandemic. Prior to COVID-19, all of the pandemics (excluding HIV) in the past century have been due to influenza viruses, and influenza remains one of the most likely future pandemic threats along with new coronaviruses. New and emerging vaccine platforms are likely to play an important role in combatting the next pandemic. However, the existing well-established, proven platforms for seasonal and pandemic influenza manufacturing will also continue to be utilized to rapidly address the next influenza threat. The field of influenza vaccine manufacturing has a long history of successes, including approval of vaccines within approximately 100 days after WHO declaration of the A(H1N1) 2009 influenza pandemic. Moreover, many advances in vaccine science and manufacturing capabilities have been made in the past decade to optimize a rapid and timely response should a new influenza pandemic threat emerge. View Full-Text
Keywords: influenza; pandemic; vaccines; vaccine manufacturing influenza; pandemic; vaccines; vaccine manufacturing
Show Figures

Figure 1

MDPI and ACS Style

Rockman, S.; Taylor, B.; McCauley, J.W.; Barr, I.G.; Longstaff, R.; Bahra, R. Global Pandemic Preparedness: Optimizing Our Capabilities and the Influenza Experience. Vaccines 2022, 10, 589.

AMA Style

Rockman S, Taylor B, McCauley JW, Barr IG, Longstaff R, Bahra R. Global Pandemic Preparedness: Optimizing Our Capabilities and the Influenza Experience. Vaccines. 2022; 10(4):589.

Chicago/Turabian Style

Rockman, Steven, Beverly Taylor, John W. McCauley, Ian G. Barr, Ray Longstaff, and Ranbir Bahra. 2022. "Global Pandemic Preparedness: Optimizing Our Capabilities and the Influenza Experience" Vaccines 10, no. 4: 589.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop